LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $20.00

LifeStance Health Group (NASDAQ:LFST) had its price objective upped by BTIG Research from $18.00 to $20.00 in a report published on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research analysts also recently issued reports on LFST. Weiss Ratings raised LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. Barclays increased their price objective on shares of LifeStance Health Group from $13.00 to $15.00 and gave the company an “overweight” rating in a research note on Thursday, September 10th. JPMorgan Chase & Co. increased their price objective on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. Canaccord Genuity Group raised their target price on shares of LifeStance Health Group from $13.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. Finally, Zacks Research cut shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $13.75.

LifeStance Health Group Stock Up 2.5%

LFST stock opened at $13.77 on Thursday. The company has a current ratio of 1.44, a quick ratio of 1.38 and a debt-to-equity ratio of 0.17. The company’s 50-day moving average price is $12.62 and its 200 day moving average price is $9.49. LifeStance Health Group has a 52 week low of $5.87 and a 52 week high of $15.66. The company has a market cap of $5.26 billion, a P/E ratio of 72.48 and a beta of 1.35.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The company had revenue of $455.86 million during the quarter, compared to analysts’ expectations of $431.59 million. LifeStance Health Group had a net margin of 4.29% and a return on equity of 4.82%. LifeStance Health Group’s revenue for the quarter was up 25.3% on a year-over-year basis. On average, research analysts expect that LifeStance Health Group will post 0.17 earnings per share for the current fiscal year.

Insider Activity at LifeStance Health Group

In related news, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of LifeStance Health Group stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $10.62, for a total transaction of $144,890,858.34. Following the completion of the sale, the insider owned 98,101,407 shares in the company, valued at approximately $1,041,836,942.34. This trade represents a 12.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CTO Vukasin Paunovich sold 42,067 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $12.87, for a total transaction of $541,402.29. Following the completion of the transaction, the chief technology officer directly owned 205,379 shares of the company’s stock, valued at $2,643,227.73. The trade was a 17.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 13,777,580 shares of company stock valued at $146,433,781 over the last quarter. Insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On LifeStance Health Group

A number of hedge funds and other institutional investors have recently modified their holdings of LFST. Capstone Investment Advisors LLC acquired a new position in LifeStance Health Group in the second quarter valued at $554,000. Bank of America Corp DE purchased a new position in LifeStance Health Group during the second quarter worth about $14,987,000. Squarepoint Ops LLC acquired a new stake in LifeStance Health Group in the 2nd quarter worth about $1,283,000. WINTON GROUP Ltd boosted its stake in LifeStance Health Group by 522.3% in the 2nd quarter. WINTON GROUP Ltd now owns 186,589 shares of the company’s stock worth $1,998,000 after buying an additional 156,607 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in LifeStance Health Group in the 2nd quarter worth about $966,000. 85.50% of the stock is currently owned by hedge funds and other institutional investors.

More LifeStance Health Group News

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: LifeStance reported Q3 adjusted earnings of $0.06 per share, ahead of estimates, and revenue of $455.9 million versus forecasts of about $431.6 million. Revenue grew 25.3% year over year, and the company raised its full-year outlook—evidence of stronger-than-expected performance. LifeStance Q3 results and outlook
• Positive Sentiment: Analysts raised their targets and maintained bullish ratings: KeyCorp lifted its target to $17 with an “overweight” rating, Canaccord Genuity raised its target to $16 with a “buy” rating, and BTIG increased its target to $20, also with a “buy” rating. These revisions signal greater optimism about potential upside. KeyCorp rating Canaccord Genuity rating BTIG target increase
• Neutral Sentiment: Coverage noted LFST reached a 52-week high and highlighted its momentum, though those signals alone do not establish whether further gains are sustainable. Zacks coverage of LFST’s high

LifeStance Health Group Company Profile

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance’s services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.